GSK5458514

DRUG2 trials

Sponsors

Ishibashi Hideyasu, GlaxoSmithKline

Conditions

Neoplasms, Prostatemetastatic castration-resistant prostate cancer

Phase 1

A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer

RecruitingNCT06990880

GlaxoSmithKlineNeoplasms, Prostate

Start: 2025-06-12End: 2028-08-09Target: 85Updated: 2026-09-18

Phase 2

A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostrate Cancer

RecruitingJPRN-jRCT2031250111

Ishibashi Hideyasumetastatic castration-resistant prostate cancer

Start: 2025-06-11Target: 7Updated: 2026-06-29